Goldman Sachs
ZVRA icon

Goldman Sachs’s Zevra Therapeutics ZVRA Stock Holding History

Goldman Sachs’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$220K Hold
23,600
– – ﹤0.01% 6039
2025
Q4 		$211K Buy
+23,600
New +$223K ﹤0.01% 6023

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Goldman Sachs's ZVRA Position: Q1 2026 in Review

Goldman Sachs increased its Zevra Therapeutics (ZVRA) stake by 26% in Q1 2026, buying an estimated $1.39M and bringing the position to 743,124 shares worth $6.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3377.

Goldman Sachs first reported a position in ZVRA in Q4 2015 and has held it in 31 quarters since. The position peaked at $7.24M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Goldman Sachs held 743,124 shares of Zevra Therapeutics worth $6.93M as of Q1 2026.
  • Goldman Sachs bought 154,424 Zevra Therapeutics shares in Q1 2026, an estimated $1.39M.
  • Zevra Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3377 holding.
  • Goldman Sachs first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 31 quarters since.
  • Goldman Sachs's Zevra Therapeutics position peaked at $7.24M in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.